What's hot
View all perspectives
David Liew drdavidliew
10 months ago
Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings.
Whether all of this is appropriate or not, we'll have to see...
#ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5
Adela Castro AdelaCastro222
10 months ago
#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9
Eric Dein ericdeinmd
10 months ago
Synovial fibroblast gene expression
Neutron-4 - plays role in axonal outgrowth, affects pain-sensitive neurons
May help explain pain in RA, possible targets
Year in Review #ACR24 Bridges
@RheumNow https://t.co/kpDVKh0C9O
Eric Dein ericdeinmd
10 months ago
Role of X chromosome in autoimmune disease?
SLE increased in Klinefelter (XXY), decreased in Turner’s (XO)
X chromosome inactivation with Xist
Inductively transgenic expression of Xist in male mice induces autoantibodies
Year in Review #ACR24 Bridges
@RheumNow https://t.co/M88f0v0kpe
Patricia Harkins DrTrishHarkins
10 months ago
Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients!
Don’t forget the 5Ms!
🧠Mind (cog/mood)
💊Medication (PIM)
🏃♀️Mobility
👉Multi-complexity
💪🏻Matters most (pt priority)
@RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX
Gabriela Martinez Zayas, MD MartinezZayasMd
10 months ago
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD
Brian Jaros, MD Dr_Brian_MD
10 months ago
EGPA: To RTX or not to RTX?
French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy
Huge anticipation for these results, hopefully next year!
#ACR24 @RheumNow https://t.co/POelLpirrI
Eric Dein ericdeinmd
10 months ago
SCN9A:
Mutations associated with primary erythromelalgia, loss of fxn in congenital inability to experience pain
Target for OA?
Nav1.7 expressed in human OA chondrocytes
Blocking in mice- decr structural jt damage, incr mouse movement
Bridges Year in Review #ACR24
@RheumNow https://t.co/AKViXGfDa6
sheila RHEUMarampa
10 months ago
Hot off the racks:
The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare rates vs PbO by depleting CD19-targeted B cells
Game changer?
Year in review.
@RheumNow #ACR24 @rheumarhyme @marklagacmd @idatan @ljdado https://t.co/CZvdrymIyr
Eric Dein ericdeinmd
10 months ago
Treatment alert for Sjogrens
TWINSS study:
Iscalimab CD40/CD40L monoclonal Ab:
Improves disease activity
Also helps fatigue and sicca, not pain
Dazodalibep - CD40L antagonist also reduce symptoms/disease activity
Year in Review #ACR24 Pillinger
@RheumNow https://t.co/WjHuEpm9XW
sheila RHEUMarampa
10 months ago
Year in review:
The MANDARA trial showed benralizumab was non-inferior to mepolizumab for #EGPA
@RheumNow #ACR24 @rheumarhyme @doktora_ging https://t.co/k5azGQOECB
Mike Putman EBRheum
10 months ago
Looking forward to this Plenary - upadacitinib vs plbo in GCA
Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks
Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉
#ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI
Eric Dein ericdeinmd
10 months ago
MANDARA
Mepolizumab v benralizumab for EGPA
BEN is non-inferior
Secondary outcomes- less eosinophils and more pts completely off GCs
Now approved for EGPA
Year in Review #ACR24 Pillinger
@RheumNow https://t.co/ThLziABvzu
Axial spondyloarthritis (axSpA) affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their reproductive age. Two interesting abstracts about reproductive issues in axSpA will be presented during the poster sessions on Saturday, November 16, 2024.
Antoni Chan MD (Prof) synovialjoints
10 months ago
With increased use of smartphones and wearables there is the opportunity to promote increased physical activity. Christine Pellegrini @RheumNow #ACR24 https://t.co/wSX3EbhVJG
Poster Hall